Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older

Trial Identifier: FBP00005
Sponsor: Sanofi Pasteur, a Sanofi Company
Start Date: August 2024
Primary Completion Date: March 2025
Study Completion Date: March 2025
Condition: Influenza Immunisation; Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AUSTRALIA MORAYFIELD, AUSTRALIA, 4506
AUSTRALIA, New South Wales BOTANY, New South Wales, AUSTRALIA, 2019
AUSTRALIA, New South Wales BROOKVALE, New South Wales, AUSTRALIA, 2100
AUSTRALIA, New South Wales MAROUBRA, New South Wales, AUSTRALIA, 2035
AUSTRALIA, New South Wales MIRANDA, New South Wales, AUSTRALIA, 2228
AUSTRALIA, Queensland SIPPY DOWNS, Queensland, AUSTRALIA, 4556
AUSTRALIA, Queensland SOUTHPORT, Queensland, AUSTRALIA, 4222
AUSTRALIA, Queensland TARINGA, Queensland, AUSTRALIA, 4068
AUSTRALIA, South Australia ADELAIDE, South Australia, AUSTRALIA, 5067
AUSTRALIA, Victoria MELBOURNE, Victoria, AUSTRALIA, 3124